[1] Avila J, DOMiNGUEZ J, Diaz-Nido J. Regulation of microtubule dynamics by microtubule-associated protein expression and phosphorylation during neuronal development. Int J Dev Biol, 2003; 38, 13−25.
[2] Ando K, Maruko-Otake A, Ohtake Y, et al. Stabilization of microtubule-unbound tau via tau phosphorylation at Ser262/356 by Par-1/MARK contributes to augmentation of AD-related phosphorylation and Aβ42-induced tau toxicity. PLOS GENET, 2016; 1, e1005917.
[3] Iijima-Ando K, Zhao L J, Gatt A, et al. A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum Mol Genet, 2010; 19, 1930−8. doi:  10.1093/hmg/ddq068
[4] Mietelska-Porowska A, Wasik U, Goras M, et al. Tau protein modifications  and  interactions:  their  role  in function and dysfunction. Review, 2014; 15, 4671−713
[5] Bennecib M, Gong CX, Grundke-Iqbal I, et al. Inhibition of PP‐2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. Febs Lett, 2001; 490, 15−22. doi:  10.1016/S0014-5793(01)02127-5
[6] Ruan Y, Zhai W, Shi X, et al. Safflower yellow ameliorates cognition deficits and reduces tau phosphorylation in APP/PS1 transgenic mice. Metab Brain Dis, 2016; 31, 1133−42. doi:  10.1007/s11011-016-9857-3
[7] de Medeiros L M, De Bastiani M A, Rico E P, et al. Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer’s Disease Studies. Mol Neurobiol, 2019; 56, 7355−67. doi:  10.1007/s12035-019-1605-3
[8] Sarkanen JR, Nykky J, Siikanen J, et al. Cholesterol supports the retinoic acid‐induced synaptic vesicle formation in differentiating human SH‐SY5Y neuroblastoma cells. J Neurochem, 2007; 102, 1941−52. doi:  10.1111/j.1471-4159.2007.04676.x
[9] Radio N M, Mundy W R. Developmental neurotoxicity testing in vitro: models for assessing chemical effects on neurite outgrowth. Neurotoxicology, 2008; 29, 361−76. doi:  10.1016/j.neuro.2008.02.011
[10] Onyango I, Dennis J, Khan S M. Mitochondrial dysfunction in Alzheimer’s disease and the rationale for bioenergetics based therapies. Aging Dis, 2016; 7, 201−14. doi:  10.14336/AD.2015.1007